Resumen
Kinins mediate their cellular effects through B1 (B1R) and B2 (B2R) receptors, and the activation of B2R reduces collagen synthesis in cardiac fibroblasts (CF). However, the question of whether B1R and/or B2R have a role in cardiac myofibroblasts remains unanswered. Methods: CF were isolated from neonate rats and myofibroblasts were generated by an 84h treatment with TGF-β1 (CMF). B1R was evaluated by western blot, immunocytochemistry and radioligand assay; B2R, inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS), and cyclooxygenases 1and 2 (COX-1, and COX-2) were evaluated by western blot; intracellular Ca +2 levels were evaluated with Fluo-4AM; collagen secretion was measured in the culture media using the picrosirius red assay kit. Results: B2R, iNOS, COX-1 and low levels of B1R but not eNOS, were detected by western blot in CF. Also, B1R, B2R, and COX-2 but not iNOS, eNOS or COX-1, were detected by western blot in CMF. By immunocytochemistry, our results showed lower intracellular B1R levels in CF and higher B1R levels in CMF, mainly localized on the cell membrane. Additionally, we found B1R only in CMF cellular membrane through radioligand displacement assay. Bradykinin (BK) B2R agonist increased intracellular Ca 2+ levels and reduced collagen secretion both in CF and CMF. These effects were blocked by HOE-140, and inhibited by L-NAME, 1400W and indomethacin. Des-Arg-kallidin (DAKD) B1R agonist did not increase intracellular Ca 2+ levels in CF; however, after preincubation for 1h with DAKD and re-stimulation with the same agonist, we found a low increase in intracellular Ca 2+ levels. Finally, DAKD increased intracellular Ca 2+ levels and decreased collagen secretion in CMF, being this effect blocked by the B1R antagonist des-Arg9-Leu8-kallidin and indomethacin, but not by L-NAME or 1400W. Conclusion: B1R, B2R, iNOS and COX-1 were expressed differently between CF and CMF, and collagen secretion was regulated differentially by kinin receptor agonists in cultured CF and CMF.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 300-308 |
Número de páginas | 9 |
Publicación | Toxicology and Applied Pharmacology |
Volumen | 261 |
N.º | 3 |
DOI | |
Estado | Published - jun. 15 2012 |
Financiación
This work was supported by the Comisión Nacional de Ciencia y Tecnología (CONICYT), Chile [ FONDECYT 1100443 to G.D.A; FONDAP 15010006 to S.L and Proyecto Anillo ACT 71 , to V.V.]. M.C., I.O., R.V. and P.A., are recipients of PhD fellowships from CONICYT, and MECESUP Chile.
Financiadores | Número del financiador |
---|---|
Comisión Nacional de Ciencia y Tecnología | |
Fondo Nacional de Desarrollo Científico y Tecnológico | ACT 71, 1100443, 15010006 |
ASJC Scopus Subject Areas
- Toxicology
- Pharmacology